# Xenon Pharmaceuticals Inc.: financial statements, quarterly

XENE · Nasdaq · CIK 1582313 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/xene.md) · [Financials](/companies/xene/financials.md) · [Filings](/companies/xene/filings.md) · [Insiders](/companies/xene/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/xene/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [0.0](/filings/0000950170-25-069342.md) | [0.0](/filings/0000950170-25-106599.md) | [0.0](/filings/0001193125-25-262646.md) | [0.0 d](/filings/0001193125-26-076650.md) | [7.5](/filings/0001193125-26-212153.md) | [0.0](/filings/0001193125-26-338244.md) | [0.0](/filings/0001193125-25-262646.md) | [0.0 d](/filings/0001193125-26-076650.md) | [0.0](/filings/0001193125-26-212153.md) | [0.0](/filings/0001193125-26-338244.md) |
| Research and development | $m | [42.9](/filings/0000950170-24-125547.md) | [41.1 d](/filings/0001193125-26-076650.md) | [44.3](/filings/0000950170-25-069342.md) | [49.7](/filings/0000950170-25-106599.md) | [57.0](/filings/0001193125-25-262646.md) | [59.5 d](/filings/0001193125-26-076650.md) | [61.2](/filings/0001193125-26-212153.md) | [75.0](/filings/0001193125-26-338244.md) | [77.1](/filings/0001193125-25-262646.md) | [87.7 d](/filings/0001193125-26-076650.md) | [88.5](/filings/0001193125-26-212153.md) | [99.2](/filings/0001193125-26-338244.md) |
| Operating income | $m | [(55.7)](/filings/0000950170-24-125547.md) | [(53.7) d](/filings/0001193125-26-076650.md) | [(59.0)](/filings/0000950170-25-069342.md) | [(69.1)](/filings/0000950170-25-106599.md) | [(73.7)](/filings/0001193125-25-262646.md) | [(77.5) d](/filings/0001193125-26-076650.md) | [(72.7)](/filings/0001193125-26-212153.md) | [(94.2)](/filings/0001193125-26-338244.md) | [(96.3)](/filings/0001193125-25-262646.md) | [(110) d](/filings/0001193125-26-076650.md) | [(112)](/filings/0001193125-26-212153.md) | [(123)](/filings/0001193125-26-338244.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(0.2)](/filings/0000950170-24-125547.md) | [(0.2) d](/filings/0001193125-26-076650.md) | [0.4](/filings/0000950170-25-069342.md) | [(0.3)](/filings/0000950170-25-106599.md) | [(0.3)](/filings/0001193125-25-262646.md) | [(3.8) d](/filings/0001193125-26-076650.md) | [0.4](/filings/0001193125-26-212153.md) | [(0.6)](/filings/0001193125-26-338244.md) | [0.7](/filings/0001193125-25-262646.md) | [0.5 d](/filings/0001193125-26-076650.md) | [(2.6)](/filings/0001193125-26-212153.md) | [(0.6)](/filings/0001193125-26-338244.md) |
| Net income | $m | [(48.5)](/filings/0000950170-24-125547.md) | [(44.7) d](/filings/0001193125-26-076650.md) | [(47.9)](/filings/0001193125-25-262646.md) | [(57.9)](/filings/0001193125-25-262646.md) | [(62.8)](/filings/0001193125-25-262646.md) | [(65.7) d](/filings/0001193125-26-076650.md) | [(65.0)](/filings/0001193125-26-338244.md) | [(84.7)](/filings/0001193125-26-338244.md) | [(90.9)](/filings/0001193125-25-262646.md) | [(105) d](/filings/0001193125-26-076650.md) | [(102)](/filings/0001193125-26-338244.md) | [(111)](/filings/0001193125-26-338244.md) |
| Diluted EPS | $ per share | [(0.73)](/filings/0000950170-24-125547.md) | not reported | [(0.62)](/filings/0000950170-25-069342.md) | [(0.75)](/filings/0000950170-25-106599.md) | [(0.81)](/filings/0001193125-25-262646.md) | not reported | [(0.83)](/filings/0001193125-26-212153.md) | [(1.07)](/filings/0001193125-26-338244.md) | [(1.15)](/filings/0001193125-25-262646.md) | not reported | [(1.17)](/filings/0001193125-26-212153.md) | [(1.11)](/filings/0001193125-26-338244.md) |
| Basic EPS | $ per share | [(0.73)](/filings/0000950170-24-125547.md) | not reported | [(0.62)](/filings/0000950170-25-069342.md) | [(0.75)](/filings/0000950170-25-106599.md) | [(0.81)](/filings/0001193125-25-262646.md) | not reported | [(0.83)](/filings/0001193125-26-212153.md) | [(1.07)](/filings/0001193125-26-338244.md) | [(1.15)](/filings/0001193125-25-262646.md) | not reported | [(1.17)](/filings/0001193125-26-212153.md) | [(1.11)](/filings/0001193125-26-338244.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [99.6](/filings/0000950170-23-061200.md) | [149](/filings/0000950170-25-029149.md) | [58.9](/filings/0000950170-24-057139.md) | [137](/filings/0000950170-24-094109.md) | [87.6](/filings/0000950170-24-125547.md) | [143](/filings/0001193125-26-076650.md) | [117](/filings/0000950170-25-069342.md) | [135](/filings/0000950170-25-106599.md) | [105](/filings/0001193125-25-262646.md) | [199](/filings/0001193125-26-338244.md) | [546](/filings/0001193125-26-212153.md) | [120](/filings/0001193125-26-338244.md) |
| Current assets | $m | [531](/filings/0000950170-23-061200.md) | [645](/filings/0000950170-25-029149.md) | [707](/filings/0000950170-24-057139.md) | [728](/filings/0000950170-24-094109.md) | [660](/filings/0000950170-24-125547.md) | [635](/filings/0001193125-26-076650.md) | [566](/filings/0000950170-25-069342.md) | [500](/filings/0000950170-25-106599.md) | [480](/filings/0001193125-25-262646.md) | [561](/filings/0001193125-26-338244.md) | [1,107](/filings/0001193125-26-212153.md) | [946](/filings/0001193125-26-338244.md) |
| Total assets | $m | [671](/filings/0000950170-23-061200.md) | [965](/filings/0000950170-25-029149.md) | [919](/filings/0000950170-24-057139.md) | [884](/filings/0000950170-24-094109.md) | [836](/filings/0000950170-24-125547.md) | [798](/filings/0001193125-26-076650.md) | [743](/filings/0000950170-25-069342.md) | [674](/filings/0000950170-25-106599.md) | [608](/filings/0001193125-25-262646.md) | [633](/filings/0001193125-26-338244.md) | [1,387](/filings/0001193125-26-212153.md) | [1,296](/filings/0001193125-26-338244.md) |
| Current liabilities | $m | [24.7](/filings/0000950170-23-061200.md) | [27.3](/filings/0000950170-25-029149.md) | [22.2](/filings/0000950170-24-057139.md) | [31.3](/filings/0000950170-24-094109.md) | [29.7](/filings/0000950170-24-125547.md) | [35.6](/filings/0001193125-26-076650.md) | [32.0](/filings/0000950170-25-069342.md) | [33.0](/filings/0000950170-25-106599.md) | [38.3](/filings/0001193125-25-262646.md) | [41.8](/filings/0001193125-26-338244.md) | [39.8](/filings/0001193125-26-212153.md) | [45.0](/filings/0001193125-26-338244.md) |
| Total liabilities | $m | [34.5](/filings/0000950170-23-061200.md) | [36.9](/filings/0000950170-25-029149.md) | [31.3](/filings/0000950170-24-057139.md) | [40.0](/filings/0000950170-24-094109.md) | [38.1](/filings/0000950170-24-125547.md) | [43.2](/filings/0001193125-26-076650.md) | [39.3](/filings/0000950170-25-069342.md) | [40.3](/filings/0000950170-25-106599.md) | [48.3](/filings/0001193125-25-262646.md) | [51.4](/filings/0001193125-26-338244.md) | [49.0](/filings/0001193125-26-212153.md) | [53.4](/filings/0001193125-26-338244.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [637](/filings/0000950170-24-125547.md) | [928](/filings/0001193125-26-076650.md) | [888](/filings/0001193125-25-262646.md) | [844](/filings/0001193125-25-262646.md) | [798](/filings/0001193125-25-262646.md) | [755](/filings/0001193125-26-338244.md) | [704](/filings/0001193125-26-338244.md) | [634](/filings/0001193125-26-338244.md) | [560](/filings/0001193125-25-262646.md) | [582](/filings/0001193125-26-338244.md) | [1,338](/filings/0001193125-26-338244.md) | [1,242](/filings/0001193125-26-338244.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(48.1) d](/filings/0000950170-24-125547.md) | [(35.4) d](/filings/0001193125-26-076650.md) | [(46.2)](/filings/0000950170-25-069342.md) | [(31.2) d](/filings/0000950170-25-106599.md) | [(49.7) d](/filings/0001193125-25-262646.md) | [(54.4) d](/filings/0001193125-26-076650.md) | [(61.7)](/filings/0001193125-26-212153.md) | [(64.2) d](/filings/0001193125-26-338244.md) | [(71.8) d](/filings/0001193125-25-262646.md) | [(81.5) d](/filings/0001193125-26-076650.md) | [(88.9)](/filings/0001193125-26-212153.md) | [(95.4) d](/filings/0001193125-26-338244.md) |
| Capital expenditure | $m | [1.2 d](/filings/0000950170-24-125547.md) | [0.1 d](/filings/0001193125-26-076650.md) | [0.2](/filings/0000950170-25-069342.md) | [1.5 d](/filings/0000950170-25-106599.md) | [0.6 d](/filings/0001193125-25-262646.md) | [0.8 d](/filings/0001193125-26-076650.md) | [0.0](/filings/0001193125-26-212153.md) | [0.2 d](/filings/0001193125-26-338244.md) | [0.3 d](/filings/0001193125-25-262646.md) | [0.3 d](/filings/0001193125-26-076650.md) | [0.1](/filings/0001193125-26-212153.md) | [0.3 d](/filings/0001193125-26-338244.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [65.5](/filings/0000950170-23-061200.md) | [65.7](/filings/0000950170-24-057139.md) | [65.9](/filings/0000950170-24-094109.md) | [66.0](/filings/0000950170-24-125547.md) | [77.6](/filings/0000950170-25-069342.md) | [77.7](/filings/0000950170-25-106599.md) | [77.9](/filings/0001193125-25-262646.md) | [78.7](/filings/0001193125-26-212153.md) | [79.0](/filings/0001193125-26-338244.md) | [79.2](/filings/0001193125-25-262646.md) | [87.3](/filings/0001193125-26-212153.md) | [99.6](/filings/0001193125-26-338244.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 96,840,432 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338244.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.